Research Analysts Set Expectations for ZVRA FY2024 Earnings
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) – Research analysts at Roth Capital lowered their FY2024 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($1.95) for the year, down […]
15 Nov 11:04 · The Markets Daily